Bevacizumab in combination with fluoropyrimidine-based chemotherapy is indicated for treatment of adult patients with metastatic carcinoma of the colon or rectum. Bevacizumab in combination with paclitaxel is indicated for first-line treatment of adult patients with metastatic breast cancer. For further information as to human epidermal growth factor receptor 2 HER2 status. Bevacizumab in combination with capecitabine is indicated for first-line treatment of adult patients with metastatic breast cancer in whom treatment with other chemotherapy options including taxanes or anthracyclines is not considered appropriate.
Patients who have received taxane and anthracycline-containing regimens in the adjuvant setting within the last 12 months should be excluded from treatment with Avastin in combination with capecitabine. For further information as to HER2 status.
Bevacizumab, in addition to platinum-based chemotherapy, is indicated for first-line treatment of adult patients with unresectable advanced, metastatic or recurrent non-small cell lung cancer other than predominantly squamous cell histology. Bevacizumab, in combination with erlotinib, is indicated for first-line treatment of adult patients with unresectable advanced, metastatic or recurrent non-squamous non-small cell lung cancer with Epidermal Growth Factor Receptor EGFR activating mutations.
Bevacizumab, in combination with carboplatin and gemcitabine, is indicated for treatment of adult patients with first recurrence of platinum-sensitive epithelial ovarian, fallopian tube or primary peritoneal cancer who have not received prior therapy with bevacizumab or other VEGF inhibitors or VEGF receptor—targeted agents.
Bevacizumab in combination with paclitaxel, topotecan, or pegylated liposomal doxorubicin is indicated for the treatment of adult patients with platinum-resistant recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who received no more than two prior chemotherapy regimens and who have not received prior therapy with bevacizumab or other VEGF inhibitors or VEGF receptor—targeted agents. Bevacizumab, in combination with paclitaxel and cisplatin or, alternatively, paclitaxel and topotecan in patients who cannot receive platinum therapy, is indicated for the treatment of adult patients with persistent, recurrent, or metastatic carcinoma of the cervix.
Please do not include any personal data , such as your name or contact details. Skip to main content. Veterinary regulatory Overview Research and development Marketing authorisation Post-authorisation. Avastin RSS. Table of contents Overview Authorisation details Product information Assessment history.
Expand section Collapse section. Avastin is used in combination with certain chemotherapy medicines in newly diagnosed patients when the cancer is advanced, or in previously treated patients whose cancer has come back recurrent. Avastin is given in combination with paclitaxel and either the platinum-based medicine cisplatin or, if this cannot be used, another chemotherapy medicine, topotecan.
Cancer of the colon or rectum In metastatic cancer of the colon or rectum, Avastin used with chemotherapy including a fluoropyrimidine has been shown to increase overall and progression-free survival in three main studies. Breast cancer In metastatic breast cancer, Avastin has been shown to increase progression-free survival in two main studies.
Non-small cell lung cancer In advanced, metastatic or recurrent lung cancer, Avastin plus platinum-based chemotherapy has been shown to increase overall survival in one study in patients: the average overall survival was In patients with a certain subtype of non-small cell lung cancer with activating mutations in the EGFR gene, Avastin plus erlotinib has been shown to increase progression-free survival in one study in patients: patients on Avastin plus erlotinib had progression-free survival of Kidney cancer In advanced or metastatic kidney cancer, Avastin plus interferon alfa-2a has been shown to increase progression-free survival in one study in patients: the average progression-free survival was Ovarian, fallopian tube and peritoneal cancer Newly diagnosed disease including advanced disease, first-line treatment : in newly diagnosed ovarian, fallopian tube and peritoneal cancer, Avastin, in combination with carboplatin and paclitaxel, has been shown to increase progression-free survival in two main studies involving 3, patients: the average progression-free survival was Recurrent disease: three studies with Avastin in recurrent ovarian, fallopian tube and peritoneal cancers were performed in a total of 1, patients.
In the first study, average progression-free survival was In the second study, overall survival in patients given Avastin in combination with carboplatin and paclitaxel was In the third study in patients with more aggressive cancer, progression-free survival was 6.
Cervical cancer In cancer of the cervix, Avastin has been shown to increase overall survival in one main study involving patients with advanced persistent, recurrent or metastatic cancer of the cervix.
Since Avastin is given with chemotherapy, you may also experience chemotherapy side effects. Create a profile for better recommendations. Breast implant illness BII is a term that some women and doctors use to refer to a wide range Sign up for emails about breast cancer news, virtual events, and more. Subscribe to our podcast for conversations on the issues that matter most. Join our online community to connect, share, and find peer support.
Was this article helpful? Can we help guide you? How does this work? Learn more. Are these recommendations helpful? Avastin was approved for metastatic breast cancer in under the accelerated approval program. Under the accelerated approval program, a drug may be approved based on results of clinical data that suggest the drug has an important clinical benefit.
However, additional information is needed to confirm the data. The FDA has proposed withdrawing Avastin's indication to treat women with metastatic breast cancer.
The agency is making this announcement after deciding there is not enough evidence that the drug is safe and effective for this one indication. The announcement will not have any immediate effect on the approval of Avastin to treat metastatic breast cancer and there will be no change to product labeling. Since the marketing approval remains in effect, patients with breast cancer will still have access to the drug until a final decision has been made.
0コメント